Recognition marks a new chapter for the oncology-focused biotechnology company as it continues development of its investigational biologic candidate targeting mechanisms associated with cancer recurrence and treatment resistance.

Creative Biotherapeutics, LLC, led by Anita Davidson, DPT, and Dr. Don Davidson, is advancing CBT300, an investigational biologic therapeutic candidate targeting drug resistance, immune evasion, recurrence, and metastasis in cancer treatment failure.

We will present preclinical data on targeting innate inflammation to prevent pancreatic cancer recurrence, improve complete response and survival rate in chemotherapy-treated mice, and overcome cancer resistance in those treated with immunotherapy.

Fluorescent guidance: a leap in bladder cancer surgery

Dr. Nicholas Franco, Urologist